Pfizer (NYSE:PFE) reported positive topline Phase 3 results from its BREAKWATER oncology trial in metastatic colorectal ...
Pfizer Inc. (NYSE:PFE) is among the Best Affordable Stocks Under $40 to Buy. On February 17, Pfizer Inc. (NYSE:PFE) announced ...
Pfizer Inc. PFE on Tuesday shared news regarding its BRAFTOVI regimen for treating metastatic colorectal cancer. Pfizer ...
The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy.
New weight loss drug by Pfizer shows promising results in trial - Pfizer acquired the drug’s developer following a bidding war with Novo Nordisk last year ...
Pfizer (PFE) stock is in focus as colorectal cancer therapy Braftovi as part of a combination regimen succeeds in a ...
GlobalData on MSN
Second Pfizer Braftovi regimen shows benefit in mCRC
This recent readout follows successful data from another combination including Braftovi in mCRC.
CHICAGO -- Pfizer has begun a Phase 2 and 3 clinical trial of its COVID-19 antiviral treatment, Paxlovid, in children ages 6 to 17, the company said Wednesday in a news release. The study will ...
Tuesday Pfizer announced it's expanding its clinical trials for younger children ages 5 to 11-years-old. Medical doctors are calling this the final frontier. This is a 2-year study, where a subset of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results